Literature DB >> 3280696

The phenotypic spectrum of histiocytosis X cells.

V Groh1, H Gadner, T Radaszkiewicz, K Rappersberger, K Konrad, K Wolff, G Stingl.   

Abstract

Proliferating cells in histiocytosis X (histiocytosis X cells) share many structural and immunophenotypic features with Langerhans cells, leading to the assumption that histiocytosis X represents a proliferative disorder of Langerhans cells. Because, depending on their state of activation and/or differentiation, Langerhans cells exhibit a varying immunophenotype, we investigated whether histiocytosis X cells display a similar phenotypic heterogeneity and, if so, whether the heterogenous biological behavior of histiocytosis X is reflected by differences in the immunophenotype of the proliferating cells. In 21 patients suffering from different clinical manifestations of histiocytosis X, proliferating cells uniformly expressed class I and II alloantigens, T200, CD1, CD4, and S100 protein. In 12 of 21 cases, histiocytosis X cells additionally exhibited immunocytochemically detectable amounts of C3b and C3bi receptors and certain monocyte/macrophage antigens (CDw14, Ki-M1, Ki-M6). This immunophenotypic heterogeneity of histiocytosis X cells could not be correlated with clinical course, prognosis, and final outcome of the disease in a given patient. The capacity of histiocytosis X cells to immunophenotypically mimic various states of Langerhans cell activation and/or differentiation, however, underscores the concept of histiocytosis X as a proliferative disorder of Langerhans cell origin.

Entities:  

Mesh:

Year:  1988        PMID: 3280696     DOI: 10.1111/1523-1747.ep12460878

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Defective alloantigen-presenting capacity of 'Langerhans cell histiocytosis cells'.

Authors:  R C Yu; J F Morris; J Pritchard; T C Chu
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

2.  Immunohistochemical study of the abnormal cells in Langerhans cell histiocytosis (histiocytosis x).

Authors:  K Ornvold; E Ralfkiaer; H Carstensen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

3.  Merkel cell carcinoma of the head and neck associated with Bowen's disease.

Authors:  P Schenk; K Konrad
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

4.  Expression of the monoclonal antibody HECA-452 defined E-selectin ligands in Langerhans cell histiocytosis.

Authors:  I Simonitsch; C W Kopp; I Mosberger; B Volc-Platzer; T Radaszkiewicz
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

5.  Multisystem Langerhans' cell histiocytosis with pancreatic involvement.

Authors:  R C Yu; A Attra; C M Quinn; T Krausz; A C Chu
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

6.  Functional defect in cells involved in Langerhans cell histiocytosis.

Authors:  R C Yu; M Alaibac; A C Chu
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

7.  The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis.

Authors:  Gerard J Nuovo; James S Hagood; Cynthia M Magro; Nena Chin; Rubina Kapil; Luke Davis; Clay B Marsh; Virginia A Folcik
Journal:  Mod Pathol       Date:  2011-10-28       Impact factor: 7.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.